menu
    • menu
    [{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Millmount Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tolvaptan","moa":"V2R","graph1":"Nephrology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Millmount Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pharmaceutical \/ Millmount Healthcare"}]

    Find Clinical Drug Pipeline Developments & Deals for Tolvaptan

    Menu

    Tolvaptan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Otsuka Pharmaceutical

                            Japan arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Otsuka Pharmaceutical

                            Japan arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tolvaptan

                            Therapeutic Area : Nephrology

                            Study Phase : Approved

                            Sponsor : Millmount Healthcare

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Samsca®Approved in Japan for Additional Indication of Hyponatremia Due to Syndrome of Inappropriate Antidiure...

                            Details : Oral vasopressin V2-receptor antagonists Samsca® Tablets, Samsca® OD Tablets and SAMSCA® Granules 1% have received regulatory approval in Japan for the indication of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secreti...

                            Brand Name : Samsca

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 29, 2020

                            Lead Product(s) : Tolvaptan

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved

                            Sponsor : Millmount Healthcare

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth